Literature DB >> 6273123

Contribution of subunits to the function of luteinizing hormone/human chorionic gonadotropin recombinants.

T W Strickland, D Puett.   

Abstract

The alpha- and beta-subunits of hCG and of ovine and porcine LH were used to prepare all nine homologous and heterologous alpha beta-recombinants. EAch purified recombinant was assayed in vitro, using dispersed Leydig tumor cells derived from the M5480P tumor, for its ability to stimulate steroidogenesis and to inhibit [125I]iodo-hCG binding. It was found that the potency of a given recombinant in both assays was most similar to that of the hormone from which the beta-subunit was derived. For example, hCG and hCG beta-containing recombinants were invariably more potent than LH and LH beta-containing recombinants. However, within groups of recombinants containing a common beta-subunit, the alpha-subunit exhibited modulatory effects on the biological potencies. The different observed potencies did not result from alpha beta dissociation since the recombinants were stable in dilute solution at 37 C for periods greatly exceeding that of the assay conditions. LH and the LH beta-containing recombinants were found to dissociate more readily from the Leydig tumor cell gonadotropin receptor than hCG and hCG beta-containing recombinants. (These experiments were performed under conditions where internalization was minimal.) However, analogous to the potency measurements, the alpha-subunit contributed to the rate of dissociation. For example, in recombinants with a common beta-subunit, hCG alpha conferred the greatest stability to the hormone-receptor interaction. These results emphasize a positive relationship between receptor occupancy and biological potency. Whereas the beta-subunit of these gonadotropins seems to exhibit the predominant influence in determining potency, it is clear that both subunits contribute to biological activity. This could involve direct effects as well as induced conformational changes in the complementary subunit.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6273123     DOI: 10.1210/endo-109-6-1933

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Molecular pharmacology of gonadotropins.

Authors:  Robert K Campbell
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

2.  Expression of human chorionic gonadotropin uniformly labeled with NMR isotopes in Chinese hamster ovary cells: an advance toward rapid determination of glycoprotein structures.

Authors:  J W Lustbader; S Birken; S Pollak; A Pound; B T Chait; U A Mirza; S Ramnarain; R E Canfield; J M Brown
Journal:  J Biomol NMR       Date:  1996-06       Impact factor: 2.835

3.  Dissociated effect of buserelin on luteinizing hormone (LH) and alpha subunit in men.

Authors:  G Valenti; L Denti; A Banchini; G Ceresini; G P Ceda; W C Westel; A Negro-Vilar
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

4.  Lutropins appear to contact two independent sites in the extracellular domain of their receptors.

Authors:  M P Bernard; R V Myers; W R Moyle
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

5.  Effect of amino group modification of ovine luteinizing hormone (oLH) by N-succinimidyl 6-[3-(2-pyridyldithio)propionate]hexanoate, a long chain N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) on immunological and biological properties: a comparative study with SPDP modified oLH.

Authors:  V Singh; R Curtiss
Journal:  Mol Cell Biochem       Date:  1994-01-12       Impact factor: 3.396

6.  A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies chromatographic behavior of luteinizing hormone in man.

Authors:  R M Evans; G C Doelle; J Lindner; V Bradley; D Rabin
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

7.  On the role of the invariant glutamine at position 54 in the human choriogonadotropin beta subunit.

Authors:  J Huang; D Puett
Journal:  Mol Cell Biochem       Date:  1994-07-27       Impact factor: 3.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.